Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer

NCT06423937 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

129

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab

Sponsor

Fudan University